Lee Troy Schalop net worth and biography

Lee Schalop Biography and Net Worth

Director of Lantern Pharma

Dr. Schalop co-founded Oncoceutics in 2009 and served in progressively senior roles, including Chief Business Officer (2009-2016), Chief Operating Officer (2016-2020), and Chief Executive Officer (2020-2021). Under his leadership, Oncoceutics advanced its targeted therapies through clinical development, ultimately leading to the company’s successful acquisition by Chimerix Inc. (NASDAQ: CMRX) for $450 million in January 2021. Following the acquisition, Dr. Schalop served as a Board Observer at Chimerix until its subsequent acquisition by Jazz Pharmaceuticals for $935 million in April 2025.

Prior to his biotech career, Dr. Schalop spent 19 years in the financial industry at major Wall Street firms including Morgan Stanley, J.P. Morgan, Credit Suisse, and Banc of America Securities, serving as both an investment banker (1985-1993) and research analyst (1993-2004). This unique combination of financial expertise and medical training has enabled him to successfully bridge the gap between scientific innovation and commercial viability.

Dr. Schalop earned his Doctor of Medicine degree from Albert Einstein College of Medicine in 2008 and he is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University’s Wharton School and College of Arts and Sciences. He currently serves on the Supervisory Board of TME Pharma N.V. (Euronext Growth Paris: ALTME) and he sits on the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania.

What is Lee Troy Schalop's net worth?: The estimated net worth of Lee Troy Schalop is at least $46.70 thousand as of May 12th, 2026. Schalop owns 48,544 shares of Lantern Pharma stock worth more than $46,699 as of October 6th. This net worth evaluation does not reflect any other investments that Schalop may own. Learn More about Lee Troy Schalop's net worth.
How do I contact Lee Troy Schalop?: The corporate mailing address for Schalop and other Lantern Pharma executives is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. Lantern Pharma can also be reached via phone at 972-277-1136 and via email at [email protected]. Learn More on Lee Troy Schalop's contact information.
Has Lee Troy Schalop been buying or selling shares of Lantern Pharma?: Lee Troy Schalop has not been actively trading shares of Lantern Pharma over the course of the past ninety days. Most recently, on Tuesday, May 12th, Lee Troy Schalop bought 48,544 shares of Lantern Pharma stock. The stock was acquired at an average cost of $2.06 per share, with a total value of $100,000.64. Following the completion of the transaction, the director now directly owns 48,544 shares of the company's stock, valued at $100,000.64. Learn More on Lee Troy Schalop's trading history.
Are insiders buying or selling shares of Lantern Pharma?: In the last year, Lantern Pharma insiders bought shares 2 times. They purchased a total of 97,088 shares worth more than $200,001.28. The most recent insider tranaction occured on May, 12th when Director Lee Troy Schalop bought 48,544 shares worth more than $100,000.64. Insiders at Lantern Pharma own 8.5% of the company. Learn More about insider trades at Lantern Pharma.
Information on this page was last updated on 5/12/2026.

Lee Troy Schalop Insider Trading History at Lantern Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/12/2026	Buy	48,544	$2.06	$100,000.64	48,544

Lee Troy Schalop Buying and Selling Activity at Lantern Pharma

Lantern Pharma Company Overview

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Today's Range

Now: $0.98

$0.92

$1.07

50 Day Range

MA: $2.01

$0.86

$2.86

2 Week Range

Now: $0.98

$0.84

$4.70

Volume

332,018 shs

Average Volume

315,183 shs

Market Capitalization

$12.48 million

P/E Ratio

N/A

Dividend Yield